Item 2.02 Results of Operations and Financial Conditions.

On August 9, 2021, Adaptimmune Therapeutics plc (the "Company") announced its financial results for the second quarter ended June 30, 2021 and provided a corporate update. A copy of the press release is being furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

The information in Item 2.02 of this Form 8-K, including the attached Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the "Exchange Act"), or incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by the Company by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.



(d)  Exhibits.

Exhibit No.                           Description of Exhibit

   99.1          Press release dated August 9, 2021.

    104        Cover Page Interactive Date File (embedded within the Inline XBRL
               document)

© Edgar Online, source Glimpses